1. Home
  2. LPTX vs PC Comparison

LPTX vs PC Comparison

Compare LPTX & PC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • PC
  • Stock Information
  • Founded
  • LPTX 2011
  • PC 2012
  • Country
  • LPTX United States
  • PC Singapore
  • Employees
  • LPTX N/A
  • PC N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • PC Restaurants
  • Sector
  • LPTX Health Care
  • PC Consumer Discretionary
  • Exchange
  • LPTX Nasdaq
  • PC Nasdaq
  • Market Cap
  • LPTX 11.1M
  • PC 12.4M
  • IPO Year
  • LPTX N/A
  • PC 2024
  • Fundamental
  • Price
  • LPTX $0.29
  • PC $7.20
  • Analyst Decision
  • LPTX Hold
  • PC
  • Analyst Count
  • LPTX 1
  • PC 0
  • Target Price
  • LPTX N/A
  • PC N/A
  • AVG Volume (30 Days)
  • LPTX 2.0M
  • PC 42.6K
  • Earning Date
  • LPTX 08-14-2025
  • PC 01-01-0001
  • Dividend Yield
  • LPTX N/A
  • PC N/A
  • EPS Growth
  • LPTX N/A
  • PC N/A
  • EPS
  • LPTX N/A
  • PC N/A
  • Revenue
  • LPTX N/A
  • PC $3,345,964.00
  • Revenue This Year
  • LPTX N/A
  • PC N/A
  • Revenue Next Year
  • LPTX N/A
  • PC N/A
  • P/E Ratio
  • LPTX N/A
  • PC N/A
  • Revenue Growth
  • LPTX N/A
  • PC N/A
  • 52 Week Low
  • LPTX $0.22
  • PC $5.11
  • 52 Week High
  • LPTX $4.79
  • PC $51.57
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 46.11
  • PC 54.74
  • Support Level
  • LPTX $0.28
  • PC $6.46
  • Resistance Level
  • LPTX $0.31
  • PC $7.02
  • Average True Range (ATR)
  • LPTX 0.04
  • PC 0.68
  • MACD
  • LPTX 0.00
  • PC 0.02
  • Stochastic Oscillator
  • LPTX 39.39
  • PC 82.84

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

About PC Premium Catering (Holdings) Limited Ordinary Shares

Premium Catering (Holdings) Ltd is a company that conducts its operations through its subsidiary is mainly engaged in food catering for functions, events, and workers in Singapore. Are specialized in Indian, Bangladesh, and Chinese cuisine and all its food products are Halal food which is permissible for consumption by Muslims to consume. Are an ACRA registered company and licensed by SFA to operate and process food business. Serve highquality value-packed food, company deliver's a reliable and dependable service to meet customer's daily meal requirements. The Company recognizes revenue from sales of budgeted prepared meals.

Share on Social Networks: